Compare Moderna, Inc. (MRNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VICI Properties Inc — how do they compare? Moderna, Inc. trades at $60.66 (market cap $23.88B), while VICI Properties Inc trades at $26.08 (market cap $28.71B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays a 6.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VICI | |
|---|---|---|
Market Cap | $23.88B | $28.71B |
Sector | Health | Real Estate |
52-Week High | $81.80 | $33.78 |
52-Week Low | $22.36 | $25.94 |
Enterprise Value | $20.03B | $46.26B |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
VICI Properties trades at $26.74, up 0.66% today, with a neutral technical signal and strong fundamentals including a 67.5% net income margin and a P/E of 10.1. Recent Q2 2026 earnings showed an EPS miss but revenue beat, while the company raised its full-year AFFO guidance. A $1.75 billion note offering in August 2026 supports capital deployment.
The outlook remains positive with a 76.9% analyst buy rating and a $29.83 consensus price target, offering potential upside. Risks include earnings volatility and high debt, but the near 7% dividend yield and stable cash flows provide investor appeal in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
